Press "Enter" to skip to content

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): How is This Stock Looking?

Checking up on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), we have noted that the average price target is currently 212.29. Individual sell-side analysts often provide their best educated projections on where a particular stock will be moving in the …Read more

Are Sarepta Therapeutics Incs NASDAQSRPT Interest Costs Too High

Small-caps and large-caps are wildly popular among investors however mid-cap stocks such as Sarepta Therapeutics Inc NASDAQSRPT with a market capitalization I wont be looking at this today but you can take a look at some of SRPTs
Read more

Sarepta Therapeutics Announces Proposed 250 Million Public Offering of Common Stock

July 24 2017 GLOBE NEWSWIRE — Sarepta Therapeutics Inc NASDAQSRPT a that are forward-looking including the statements about the completion timing and size of the proposed public offering of Sareptas common stock within the meaning
Read more

Sarepta Therapeutics Inc This Chart Shows Where SRPT Stock Could Go Next

Sarepta Therapeutics Inc NASDAQSRPT stock has had a difficult year gaining traction The weight placed on this one drug is so heavy it is causing wild and erratic swings in SRPT stock Looking at the chart below you can see the gaps in the share
Read more

Is Sarepta Therapeutics Inc SRPT A Good Stock To Buy

Lets look at how this market volatility affected the sentiment of hedge funds towards Sarepta Therapeutics Inc NASDAQSRPT and what that likely means for the prospects of the company and its stock If youd ask most stock holders hedge funds are
Read more

How Sarepta Is Cashing In on Its FDA Homerun

Sarepta Therapeutics Inc NASDAQ SRPT watched its stock practically double in just the past week the departure of Sareptas lead critic changed the game Now Sarepta is looking to cash in on this approval by announcing a secondary offering
Read more

Sarepta Therapeutics Inc SRPT Stock Heads Higher on Analyst Upgrade

Sarepta Therapeutics Inc NASDAQSRPT stock was up on Thursday following an upgrade from reports Barrons Wall Street is looking for Sarepta Therapeutics Inc to report revenue of 2174 million during the first quarter of 2017
Read more

Please follow and like us:

Comments are closed.